肠道菌群与肺癌的相关性

Correlation between Gut Microbiota and Lung Cancer

基因-环境相互作用是癌症易感性和进展的基础。人体长期暴露于各种微生物所构成的微环境中并受其影响,如肠道菌群所构成的微环境。肺癌患者中某些肠道微生物的相对丰度与对照组相比存在显著差异。这些研究表明,肠道菌群可能通过某些途径与肺癌相关联。同时,与我们所暴露的外部环境相比,肠道菌群相对而言是易控制的环境变量,因为它们在个体内是高度可量化和相对稳定的。正如某些靶向肠道菌群的肺癌的诊断、干预、治疗的措施已在临床取得一定效果。在这篇综述中,我们主要讨论了肠道菌群通过某些途径,如通过调控代谢、炎症以及免疫反应影响肺癌的发生发展以及治疗。根据当前的研究进展推断:针对肠道菌群的研究或将是肺癌进行精准和个性化医疗的有效途径。

Gene-environment interactions underlie cancer susceptibility and progression. The human body is exposed to and affected by the microenvironment seiscasts of various microorganisms and their metabolites, such as the microenvironment of gut microbiota. The relative abundance of some intestinal microbes in lung cancer patients was significantly different from that in the control group. These studies suggest that gut microbiota may be associated with lung cancer through some ways. At the same time, gut microbiota is relatively manageable environmental variables compared to the external environment we are exposed to, as they are highly quantifiable and relatively stable in the individual. Just as some measures of diagnosis, intervention and treatment of lung cancer targeting gut microbiota have achieved some results in clinical practice. In this review, we mainly discuss the role of gut microbiota and its metabolites in the progression and treatment of lung cancer through certain ways, such as regulation of metabolism, inflammation, and immune response. Finally, based on current research progress, it is inferred that research on gut microbiota may be an effective approach to the precise and personalized medical treatment of lung cancer.